Clinical Trials Browser

Phase 1 × Lymphoma, T-Cell, Peripheral × Azacitidine × Clear all

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Phase 1 Completed

26 enrolled 24 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT01129180 2013-12-03

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Phase 1 Completed

8 enrolled

DermatologicLymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Sezary Syndrome, Leukemia, Prolymphocytic, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Leukemia, Large Granular Lymphocytic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

Clinical Trials

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma